Microbial resistance is one of the main problems of modern medicine. Recently, antimicrobial peptides have been recognized as a novel approach to overcome the microbial resistance issue, nevertheless, their low stability, toxicity, and potential immunogenic response in biological systems have limited their clinical application. Herein, we present the design, synthesis, and preliminary biological evaluation of polymer-antibacterial peptide constructs. The antimicrobial GKWMKLLKKILK-NH2 oligopeptide (PEP) derived from halictine, honey bee venom, was bound to a polymer carrier via various biodegradable spacers employing the pH-sensitive or enzymatically-driven release and reactivation of the PEP's antimicrobial activity. The antibacterial properties of the polymer-PEP constructs were assessed by a determination of the minimum inhibitory concentrations, followed by fluorescence and transmission electron microscopy. The PEP exerted antibacterial activity against both, gram-positive and negative bacteria, via disruption of the bacterial cell wall mechanism. Importantly, PEP partly retained its antibacterial efficacy against Staphylococcus epidermidis, Escherichia coli, and Acinetobacter baumanii even though it was bound to the polymer carrier. Indeed, to observe antibacterial activity similar to the free PEP, the peptide has to be released from the polymer carrier in response to a pH decrease. Enzymatically-driven release and reactivation of the PEP antimicrobial activity were recognized as less effective when compared to the pH-sensitive release of PEP.

Department of Biochemistry and Microbiology University of Chemistry and Technology Prague Technická 3 166 28 Prague Czech Republic

Institute of Macromolecular Chemistry Czech Academy of Sciences Heyrovského nám 2 162 00 Prague Czech Republic

Zobrazit více v PubMed

Seaworth B.J., Griffith D.E. Therapy of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis. Microbiol. Spectr. 2017;5:1–28. doi: 10.1128/microbiolspec.TNMI7-0042-2017. PubMed DOI PMC

World Health Organization . Global Tuberculosis Report 2021. World Health Organization; Geneva, Switzerland: 2021.

Mintz P.D. WHO Publishes List of Bacteria for Which New Antibiotics Are Urgently Needed Thereby Highlighting the Requirement for Further Vigilance for Platelet Transfusions. World Health Organization; Geneva, Switzerland: 2017. pp. 3–4.

Asokan G., Ramadhan T., Ahmed E., Sanad H. WHO Global Priority Pathogens List: A Bibliometric Analysis of Medline-PubMed for Knowledge Mobilization to Infection Prevention and Control Practices in Bahrain. Oman Med. J. 2019;34:184–193. doi: 10.5001/omj.2019.37. PubMed DOI PMC

Griffith D.E., Aksamit T.R. Understanding nontuberculous mycobacterial lung disease: It’s been a long time coming. F1000Research. 2016;5:2797–2805. doi: 10.12688/f1000research.9272.1. PubMed DOI PMC

Cândido P.H.C., De Nunes L.S., Marques E.A., Folescu T.W., Coelho F.S., De Moura V.C.N., Da Silva M.G., Gomes K.M., Lourenço M.C.D.S., Aguiar F.S., et al. Multidrug-resistant nontuberculous mycobacteria isolated from cystic fibrosis patients. J. Clin. Microbiol. 2014;52:2990–2997. doi: 10.1128/JCM.00549-14. PubMed DOI PMC

Zasloff M. Antimicrobial peptides of multicellularorganisms. Nature. 2002;415:389–395. doi: 10.1038/415389a. PubMed DOI

Bulet P., Stöcklin R., Menin L. Anti-microbial peptides: From invertebrates to vertebrates. Immunol. Rev. 2004;198:169–184. doi: 10.1111/j.0105-2896.2004.0124.x. PubMed DOI

Hale J.D.F., Hancock R.E.W. Alternative mechanisms of action of cationic antimicrobial peptides on bacteria. Expert Rev. Anti. Infect. Ther. 2007;5:951–959. doi: 10.1586/14787210.5.6.951. PubMed DOI

Steckbeck J.D., Deslouches B., Montelaro R.C. Antimicrobial peptides: New drugs for bad bugs? Expert Opin. Biol. Ther. 2014;14:11–14. doi: 10.1517/14712598.2013.844227. PubMed DOI PMC

Vicent M.J., Manzanaro S., de la Fuente J.A., Duncan R. HPMA copolymer-1,5-diazaanthraquinone conjugates as novel anticancer therapeutics. J. Drug Target. 2004;12:503–515. doi: 10.1080/10611860400011901. PubMed DOI

Fox J.L. Antimicrobial peptides stage a comeback. Nat. Biotechnol. 2013;31:379–382. doi: 10.1038/nbt.2572. PubMed DOI

Monincová L., Buděšínsky M., Slaninová J., Oldřich Hovorka O., Cvačka J., Voburka Z., Fučík V., Borovičková L., Bednárová L., Straka J., et al. Novel antimicrobial peptides from the venom of the eusocial bee Halictus sexcinctus (Hymenoptera: Halictidae) and their analogs. Amino Acids. 2010;39:763–775. doi: 10.1007/s00726-010-0519-1. PubMed DOI

Melicherčík P., Nešuta O., Čeřovský V. Antimicrobial Peptides for Topical Treatment of Osteomyelitis and Implant-Related Infections: Study in the Spongy Bone. Pharmaceuticals. 2018;11:20. doi: 10.3390/ph11010020. PubMed DOI PMC

Ulbrich K., Holá K., Šubr V., Bakandritsos A., Tuček J., Zbořil R. Targeted Drug Delivery with Polymers and Magnetic Nanoparticles: Covalent and Noncovalent Approaches, Release Control, and Clinical Studies. Chem. Rev. 2016;116:5338–5431. doi: 10.1021/acs.chemrev.5b00589. PubMed DOI

Letai A. S63845, an MCL-1 Selective BH3 Mimetic: Another Arrow in Our Quiver. Cancer Cell. 2016;30:834–835. doi: 10.1016/j.ccell.2016.11.016. PubMed DOI

Subr V., Etrych T., Ulbrich K., Hirano T., Kondo T., Todoroki T., Jelinkova M., Rihova B. Synthesis and properties of poly{[}N-(2-hydroxypropyl) methacrylamide] conjugates of superoxide dismutase. J. Bioact. Compat. Polym. 2002;17:105–122.

Tang Z., Ma Q., Chen X., Chen T., Ying Y., Xi X., Wang L., Ma C., Shaw C., Zhou M. Recent Advances and Challenges in Nanodelivery Systems for Antimicrobial Peptides (AMPs) Antibiotics. 2021;10:990. doi: 10.3390/antibiotics10080990. PubMed DOI PMC

Cayot P., Tainturier G. The quantification of protein amino groups by the trinitrobenzenesulfonic acid method: A reexamination. Anal. Biochem. 1997;249:184–200. doi: 10.1006/abio.1997.2161. PubMed DOI

Ulbrich K., Šubr V., Strohalm J., Plocová D., Jelínková M., Říhová B. Polymeric drugs based on conjugates of synthetic and natural macromolecules. I. Synthesis and physico-chemical characterisation. J. Control. Release. 2000;64:63–79. doi: 10.1016/S0168-3659(99)00141-8. PubMed DOI

Pola R., Parnica J., Zuska K., Böhmová E., Filipová M., Pechar M., Pankrác J., Mucksová J., Kalina J., Trefil P., et al. Oligopeptide-targeted polymer nanoprobes for fluorescence-guided endoscopic surgery. Multifunct. Mater. 2019;2:024004. doi: 10.1088/2399-7532/ab159e. DOI

Chytil P., Etrych T., Kříž J., Subr V., Ulbrich K. N-(2-Hydroxypropyl)methacrylamide-based polymer conjugates with pH-controlled activation of doxorubicin for cell-specific or passive tumour targeting. Synthesis by RAFT polymerisation and physicochemical characterisation. Eur. J. Pharm. Sci. 2010;41:473–482. doi: 10.1016/j.ejps.2010.08.003. PubMed DOI

Pola R., Janoušková O., Etrych T. The pH-Dependent and Enzymatic Release of Cytarabine from Hydrophilic Polymer Conjugates. Physiol. Res. 2016;65:225–232. doi: 10.33549/physiolres.933424. PubMed DOI

Perrier S., Takolpuckdee P., Westwood J., Lewis D.M. Versatile Chain Transfer Agents for Reversible Addition Fragmentation Chain Transfer (RAFT) Polymerization to Synthesize Functional Polymeric Architectures. Macromolecules. 2004;37:2709–2717. doi: 10.1021/ma035468b. DOI

Chytil P., Koziolová E., Etrych T., Ulbrich K. HPMA Copolymer–Drug Conjugates with Controlled Tumor-Specific Drug Release. Macromol. Biosci. 2018;18:1700209. doi: 10.1002/mabi.201700209. PubMed DOI

Kopeček J., Kopečková P. HPMA copolymers: Origins, early developments, present, and future. Adv. Drug Deliv. Rev. 2010;62:122–149. doi: 10.1016/j.addr.2009.10.004. PubMed DOI PMC

Randárová E., Kudláčová J., Etrych T. HPMA copolymer-antibody constructs in neoplastic treatment: An overview of therapeutics, targeted diagnostics, and drug-free systems. J. Control. Release. 2020;325:304–322. doi: 10.1016/j.jconrel.2020.06.040. PubMed DOI

Zdzalik M., Karim A.Y., Wolski K., Buda P., Wojcik K., Brueggemann S., Wojciechowski P., Eick S., Calander A.-M., Jonsson I.-M., et al. Prevalence of genes encoding extracellular proteases in Staphylococcus aureus—Important targets triggering immune response in vivo. FEMS Immunol. Med. Microbiol. 2012;66:220–229. doi: 10.1111/j.1574-695X.2012.01005.x. PubMed DOI

Kalińska M., Kantyka T., Greenbaum D.C., Larsen K.S., Władyka B., Jabaiah A., Bogyo M., Daugherty P.S., Wysocka M., Jaros M., et al. Substrate specificity of Staphylococcus aureus cysteine proteases—Staphopains A, B and C. Biochimie. 2012;94:318–327. doi: 10.1016/j.biochi.2011.07.020. PubMed DOI

Pechar M., Pola R., Studenovský M., Bláhová M., Grosmanová E., Dydowiczová A., Filipová M., Islam R., Gao S., Fang J., et al. Polymer nanomedicines with enzymatically triggered activation: A comparative study of in vitro and in vivo anti-cancer efficacy related to the spacer structure. Nanomed. Nanotechnol. Biol. Med. 2022;46:9–12. doi: 10.1016/j.nano.2022.102597. PubMed DOI

Volejníková A., Melicherčík P., Nešuta O., Vaňková E., Bednárová L., Rybáček J., Čeřovský V. Antimicrobial peptides prevent bacterial biofilm formation on the surface of polymethylmethacrylate bone cement. J. Med. Microbiol. 2019;68:961–972. doi: 10.1099/jmm.0.001000. PubMed DOI

Sánchez-Clemente R., Igeño M.I., Población A.G., Guijo M.I., Merchán F., Blasco R. Study of pH Changes in Media during Bacterial Growth of Several Environmental Strains. Proceedings. 2018;2:1297.

Wilhelm M.J., Sharifian Gh. M., Wu T., Li Y., Chang C.-M., Ma J., Dai H.-L. Determination of bacterial surface charge density via saturation of adsorbed ions. Biophys. J. 2021;120:2461–2470. doi: 10.1016/j.bpj.2021.04.018. PubMed DOI PMC

Šálek P., Trousil J., Nováčková J., Hromádková J., Mahun A., Kobera L. Poly [2-(dimethylamino)ethyl methacrylate- co -ethylene dimethacrylate]nanogel by dispersion polymerization for inhibition of pathogenic bacteria. RSC Adv. 2021;11:33461–33470. doi: 10.1039/D1RA06231J. PubMed DOI PMC